New hope for lung cancer patients: lorlatinib targets resistant tumors

NCT ID NCT03909971

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tested the drug lorlatinib in 109 people in China with advanced ALK-positive non-small cell lung cancer whose disease had progressed after treatment with other ALK inhibitors. The goal was to see how many patients' tumors shrank or disappeared. The trial is now complete, and results may show whether lorlatinib can help control the disease in this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorlatinib (a drug that targets ALK-positive lung cancer)
What this could lead to: If successful, lorlatinib could offer a new treatment option for people with ALK-positive lung cancer whose disease has worsened after other ALK inhibitors.
What could go wrong: This is a Phase 2 trial with a small number of participants (109) and no comparison group, so results may not confirm effectiveness or safety for broader use. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Beijing Chest Hospital, Capital Medical University

Beijing, 101149, China
Fifth Medical Center of PLA General Hospital

Beijing, 100071, China
Fudan University Shanghai Cancer Center

Shanghai, 200032, China
Fujian Province Oncology Hospital

Fuzhou, Fujian, 350014, China
Gaoxin Hospital of The First Affilated Hospital of Anhui Medical University

Hefei, Anhui, 230088, China
General Hospital of Eastern Theater Command

Nanjing, China
Guangdong Provincial People's Hospital

Guangzhou, 510000, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Hunan Provincial Tumor Hospital/Division of Oncology

Changsha, Hunan, 410013, China
Jilin Provincial Cancer Hospital

Changchun, Jilin, 130103, China
Shanghai Chest Hospital

Shanghai, 200030, China
Sichuan Province Cancer Hospital/Department of Pulmonary Tumor

Chengdu, Sichuan, 610041, China
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology

Hangzhou, Zhejiang, 310016, China
Tangdu Hospital of Fourth Military Medical University

Xi’an, Shanxi, 710000, China
The First Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, 310003, China
The Second Affiliated Hospital of Zhejiang University College of Medicine

Hangzhou, Zhejiang, 310009, China
The first hospital of jilin university

Changchun, Jilin, 130021, China
West China Hospital, Sichuan University, Cancer center

Chengdu, Sichuan, 610041, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China
Zhongshan Hospital, Fudan University

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.